Price
No data yet.
Social Signal Score
Analyst Ratings
10 analystsRevenue
$39.66MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Neil F. McFarlane
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 61
- Beta
- 0.95
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 4.46
Financials
Revenue
$39.66M+246.0%Net Income
$8.75MEBITDA
$13.11MFree Cash Flow
$16.82MEPS (diluted)
$0.14Shares Outstanding (diluted)
61.34M+6600.3%Operating Expenses
$21.05MCash & Debt
$221.57MReturn of Capital
$0.00Revenue by Segment (annual)
$18.00MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $106.47M | $83.23M | $1.40 |
| 2024 | $23.61M | $-105.51M | $-2.28 |
| 2023 | $27.46M | $-46.05M | $-1.30 |
| 2022 | $10.16M | $-26.77M | $-0.78 |
| 2021 | $28.65M | $-8.55M | $-2.11 |
| 2020 | $13.29M | $-12.76M | $-3.21 |
| 2019 | $12.84M | $-24.52M | $-13.23 |
| 2018 | $0.00 | $-56.47M | $-50.39 |
| 2017 | $0.00 | $-43.39M | $-47.37 |
| 2016 | $0.00 | $-16.52M | $-18.10 |
| 2015 | $0.00 | $-54.66M | $-118.69 |
| 2014 | $0.00 | $-24.45M | $-31.79 |
| 2013 | $0.00 | $-5.23M | $-10.69 |
| 2012 | $0.00 | $-70.4K | $-0.47 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $2.21
- Implied price
- $13.27
- Return from $9.99
- 5.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $6.60 — -34.0% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 2 | 4 | 6 | 8 | 10 |
|---|---|---|---|---|---|
| -2.0% | -22.9% | -11.4% | -4.0% | 1.7% | 6.4% |
| 3.0% | -19.0% | -6.9% | 0.9% | 6.9% | 11.8% |
| 8.0% | -15.0% | -2.4% | 5.8% | 12.1% | 17.2% |
| 13.0% | -11.1% | 2.1% | 10.7% | 17.3% | 22.6% |
| 18.0% | -7.2% | 6.6% | 15.6% | 22.5% | 28.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
120+9.09%Social Signal Score
Mentions (3)
- Newsseekingalpha.com·6h ago·Positive
Zevra Therapeutics: Miplyffa Validates The Bull Case, Europe Still The Swing Factor Zevra Therapeutics is a buy-rated, single-asset rare disease play with Miplyffa driving strong U.S. growth and early profitability. 2Q26 net revenue reached $39.7M, up 53% YoY, with Miplyffa contributing $30.2M and high patient retention supporting a durable franchise thesis. Management's diagnosis expansion efforts suggest the NPC addressable market may be up to 900 patients, extending the growth runway beyond i
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
Zevra Therapeutics to Present at Upcoming Investor Conferences BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that members of Zevra's executive leadership team will present at the following investor conferences in New York, NY.
View source ↗ - Newsglobenewswire.com·42d ago·Positive
…ta on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium BOSTON, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced the presentation of two posters featuring long-term real-world data on MIPLYFFA® (arimoclomol) for the treatment of Niemann-Pick disease type C (NPC) at the Society for the Stu…
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $0.14 per share
Typical surprise +50.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$0.14 vs $0.11beat
- Wed, May 6$0.60 vs $0.06beat
- Mon, Mar 9$0.21 vs $0.05beat
- Wed, Nov 5$-0.01 vs $-0.02beat
- Tue, Aug 12$1.21 vs $2.19miss
- Tue, May 13$-0.06 vs $-0.21beat
Estimates and results for ZVRA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ZVRA officers and directors.
- Bought
- $310k
- Sold
- $3.6m
5 trades
19 trades
- Thompson Rahsaansold
- Watton Corey Michaelsold
- Thompson Rahsaansold
- Thompson Rahsaansold
- Mcfarlane Neil F.sold
- Sangiovanni Timothy J.sold
- Schafer Joshuasold
- Mcfarlane Neil F.sold
76 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ZVRA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.